Not checkedNot checked for notices yet.
NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus
Hans D. Brightbill, Eric Suto, Nicole Blaquiere and 32 more
Nature Communications · 2018
doi:10.1038/s41467-017-02672-0 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK with a similar efficacy to BAFF inhibition in two mouse models of SLE.
Abstract licence: CC BY-NC-ND
Cited by papers we hold3
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.